TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04547244

Intervention type: OTHER
Intervention: echocardiographic optimization of CRTd
Description: the patients after the implant of CRTd and during the follow-up will receive an echocardiography to optimize the atrio-ventricular and inter-ventricular delay, and to improve the effects of CRTd.
Study: NCT04162886

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Thrower's ten exercises will given for 8 weeks, 3 days in a week.
Study: NCT02153385

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Yoga program was 60 min per session, twice per week for 8 weeks. Led by an experienced yoga instructor.
Study: NCT02409160

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Roux-en-Y gastric bypass
Study: NCT04323397

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation
Description: Intervention nasal high frequency oscillatory ventilation (nHFOV) and nasal synchronized intermittent positive pressure ventilation (nSIPPV) were generated by neonatal ventilators (SLE6000 infant ventilators, United Kingdom) using bi-nasal prongs (RAM cannula, NEOTECH®, USA) or the nasal mask of the same type for both ventilation modes. The size of the prongs was determined by the infant's weight. The largest possible prongs were used, with a snug fit to avoid leakage. Pacifier for preterm and term neonate (Jollypop™, USA) was taken to avoid leakage from the mouth. The disposable ventilator circuit (Fisher \& Paykel RT268™, Evaqua Dual Limb Infant Breathing Circuit Kit with Evaqua 2 Technology and Pressure Line, Flow \> 4L/min, New Zealand) was used. The initial NIV setting was (7) described in arm description. (above)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation
Description: Intervention nasal high frequency oscillatory ventilation (nHFOV) and nasal synchronized intermittent positive pressure ventilation (nSIPPV) were generated by neonatal ventilators (SLE6000 infant ventilators, United Kingdom) using bi-nasal prongs (RAM cannula, NEOTECH®, USA) or the nasal mask of the same type for both ventilation modes. The size of the prongs was determined by the infant's weight. The largest possible prongs were used, with a snug fit to avoid leakage. Pacifier for preterm and term neonate (Jollypop™, USA) was taken to avoid leakage from the mouth. The disposable ventilator circuit (Fisher \& Paykel RT268™, Evaqua Dual Limb Infant Breathing Circuit Kit with Evaqua 2 Technology and Pressure Line, Flow \> 4L/min, New Zealand) was used. The initial NIV setting was (7) described in arm description. (above)
Study: NCT01818167

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10% Benzoyl Peroxide Topical Body Wash

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Provodine Topical Cream
Study: NCT03634605

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chemical pleurodesis

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Chemical pleurodesis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracycline Topical Ointment
Study: NCT02991885

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HAL-MPE1
Description: Weekly subcutaneous administrations of HAL-MPE1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HAL-MPE1 placebo
Description: Weekly subcutaneous administrations of HAL-MPE1 placebo
Study: NCT03135353

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D saline infusion sonohysterography
Description: instillation of saline in the uterine cavity using pediatric foley's catheter, then performing 3D ultrasound scan of the uterus and adenexae

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Office Hysteroscopy
Description: an outpatient procedure done to assess the uterine cavity using the office hysteroscopy
Study: NCT02662244

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser
Description: Long-Pulsed 1064 NM ND:Yag Laser Treatment Of Basal Cell Carcinoma
Study: NCT01115998

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Power wheelchair
Description: Children used power wheelchairs for one year. They continued to receive their usual early intervention services.

Intervention type: OTHER
Group type: OTHER
Intervention: No power wheelchairs
Description: Children in the control group did not use power wheelchairs. They continued to receive their usual early intervention services.
Study: NCT00973947

Intervention type: OTHER
Group type: OTHER
Intervention: questionnaire administration

Intervention type: OTHER
Group type: OTHER
Intervention: questionnaire administration

Intervention type: RADIATION
Group type: OTHER
Intervention: 3-dimensional conformal radiation therapy

Intervention type: RADIATION
Group type: OTHER
Intervention: 3-dimensional conformal radiation therapy

Intervention type: RADIATION
Group type: OTHER
Intervention: radiation therapy treatment planning/simulation

Intervention type: RADIATION
Group type: OTHER
Intervention: radiation therapy treatment planning/simulation
Study: NCT01268059

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin (carboplatin area under the plasma concentration-time curve \[AUC\] of 6 milligram per milliliter into minute \[mg/mL\*min\] administered as an intravenous (IV) infusion once every 21 days on Day 1, for a total of 6 doses (cycles) until unacceptable toxicity, disease progression, or other reasons for participant withdrawal.
Study: NCT03634605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 2% Injectable Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine 2% Injectable Solution
Study: NCT00863785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticoids plus N Acetyl Cysteine
Description: 40 mg/d prednisolone N Acetyl Cysteine infusion 150mg/kg in 30 minutes then 50 mg/kg in 4 h then 100mg/kg in 16 h and finally 100mg/d2 to d5
Study: NCT01268059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin (carboplatin area under the plasma concentration-time curve \[AUC\] of 6 milligram per milliliter into minute \[mg/mL\*min\] administered as an intravenous (IV) infusion once every 21 days on Day 1, for a total of 6 doses (cycles) until unacceptable toxicity, disease progression, or other reasons for participant withdrawal.
Study: NCT01781312

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ProTectis

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gastrus
Study: NCT03924154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVT-1201
Description: RVT-1201 600 mg immediate-release tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive pill manufactured to mimic RVT-1201 600 mg immediate-release tablet
Study: NCT03086135

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Osia System
Description: An external Sound Processor captures and digitize the sound which is transferred to the internal implant where it is converted to an electrical signal. The electrical signal is further transferred as a vibration through an osseointegrated implant to the mastoid bone and eventually to the cochlea.
Study: NCT01984606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Empagliflozin once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching empagliflozin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Sitagliptin once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo matching sitagliptin
Study: NCT00274625

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgisis Gold Graft
Description: Surgisis Gold Graft is placed as an underlay following open bariatric surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Incision is closed without the placement of a graft material (standard of care control)
Study: NCT00352196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: 12 weeks of treatment with risperidone 0.25 to 11 mg per day.

Intervention type: DRUG
Group type: OTHER
Intervention: Risperidone
Description: 12 weeks of treatment with risperidone 0.25 to 11 mg per day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Spectroscopy
Description: Subjects will receive a standard MRS to assess the concentrations and ratios of brain metabolites N-acetylaspartate, creatine, phosphocreatine, and choline.
Study: NCT02684539

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tilt table Erigo®
Description: tilting table with onset of syncope
Study: NCT03646409

Intervention type: OTHER
Intervention: Venous thromboembolic event, arterial thromboembolic event, bleeding events
Description: Whether or not venous or arterial thromboembolic and bleeding events occur in patients with esophageal cancer receiving neoadjuvant chemotherapy
Study: NCT01251393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biperiden
Description: Thirty volunteers will take three pills of Biperiden (6mg/day) during two months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Thirty volunteers will take three pills of Placebo (6mg/day) during two months.
Study: NCT02945072

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TIVA
Description: TIVA is use to anesthesia maintenance after anesthesia induction (Propofol 10mg/kg/h, Remifentanil 0.2mcg/kg/min, dose adaptation as required for sufficient anesthesia)
Study: NCT01268059

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 200 milligram per square meter (mg/m\^2) administered as an intravenous (IV) infusion once every 21 days on Day 1, for a total of 6 doses (cycles) until unacceptable toxicity, disease progression, or other reasons for participant withdrawal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 200 milligram per square meter (mg/m\^2) administered as an intravenous (IV) infusion once every 21 days on Day 1, for a total of 6 doses (cycles) until unacceptable toxicity, disease progression, or other reasons for participant withdrawal.
Study: NCT02945072

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Sevoflurane is use to anesthesia maintenance after anesthesia induction (target et 2 Vol% in 50-70% N2O, dose adaptation as required)
Study: NCT02316548

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Postoperative adjuvant IMRT radiotherapy 50.4 Gy in 28 fractions. In patients not getting postoperative adjuvant chemotherapy the radiation treatment must begin within 140 days after cystectomy. For patients getting adjuvant chemotherapy radiation treatment must start within 49 days of completing chemotherapy.
Study: NCT05718050

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Mandibular flexure evaluation
Description: A mandibular silicon impression was taken, and a vacuum molded thermoplastic stent with radiopaque fiducial markers (steel ball bearings) on the facial side of the canines and molars was fabricated for each patient. Two Cone Beam Computed Tomographs (CBCTs) were made per patient with their radiographic stent in the mouth at the OVD and MO positions at the University Advanced Digital Diagnostic Center. The CBCT examination was performed without any stitching procedure using a computed tomography (SCANORA 3DX; Dexis LLC) set up at 90 kV, 4 mA and a field of view (FOV) of 140 and 100 mm in height and width respectively, to decrease the radiation dose without affecting the quality of the examination.
Study: NCT03137771

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy (3D-CRT)
Description: Undergo 3DCRT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV
Study: NCT01268059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-575
Description: MEDI-575 at a dose of 25 milligram per kilogram (mg/kg) administered as an IV infusion once every 21 days on Day 1 for a total of 6 cycles until unacceptable toxicity, disease progression, initiation of alternative anticancer therapy, or other reasons for participant withdrawal. MEDI-575 alone continued in those participants who achieved stable disease or better at the completion of carboplatin/paclitaxel therapy and did not demonstrate toxicity to MEDI-575.
Study: NCT00061100

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior Therapy-RISE
Description: manually-guided HIV intervention RISE: Reduce high risk Intravenous drug use and unsafe Sexual Encounter

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard prevention Education
Description: standard psychosocial Education for HIV/hepatitis prevention
Study: NCT03137771

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy (IMRT)
Description: Undergo IMRT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed Disodium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed Disodium
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: Undergo SBRT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib Hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT01386112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EUR-1100
Description: Active oral medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EUR-1100
Description: Active oral medication

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo
Study: NCT03660943

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Receiving Placebo Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTX-4975-05
Description: Receiving CNTX-4975-05 Injection
Study: NCT01713387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine, S-1
Description: Dose of gemcitabine and S-1 and treatment schedule
Study: NCT03114943

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NBP608
Description: Preparation of the Oka/SK strain of live, attenuated varicella virus

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Varivax
Description: Preparation of the Oka/Merck strain of live, attenuated varicella virus
Study: NCT02920047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimasartan + Amlodipine
Description: Treatment A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimasartan + Amlodipine
Description: Treatment A
Study: NCT00224133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silodosin
Description: 8 mg daily
Study: NCT04123665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stannous fluoride
Description: In this arm, participants will apply a full ribbon of dentifrice ( 0.454% w/w stannous fluoride) to the bristles of a study toothbrush and brush their teeth in their usual manner for one timed minute twice daily (morning and evening) and record on their study diary completed brushings.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium monofluorophosphate
Description: In this arm, participants will apply a full ribbon of negative control dentifrice (1000 ppm fluoride as SMFP to the bristles of a study toothbrush and brush their teeth in their usual manner for one timed minute twice daily (morning and evening) and record on their study diary completed brushings.
Study: NCT00664027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTA 402 (Bardoxolone Methyl)
Description: Stratum 1: 25, 75, 150mg/day, orally, 28 consecutive days Stratum 2: 25 mg/day, orally, 28 consecutive days followed by 75 mg/day, orally, 28 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTA 402 (Bardoxolone Methyl)
Description: Stratum 1: 25, 75, 150mg/day, orally, 28 consecutive days Stratum 2: 25 mg/day, orally, 28 consecutive days followed by 75 mg/day, orally, 28 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTA 402 (Bardoxolone Methyl)
Description: Stratum 1: 25, 75, 150mg/day, orally, 28 consecutive days Stratum 2: 25 mg/day, orally, 28 consecutive days followed by 75 mg/day, orally, 28 consecutive days
Study: NCT00827944

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Parietex Progrip
Description: Surgical technique:~Self-gripping lightweight Polyester and Polylactic acid meshes providing a sutureless fixation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low weight polypropylene mesh
Description: Surgical technique:~Lichtenstein repair with lightweight polypropylene mesh (inferior to 70gr/m2) secured to the posterior inguinal wall with sutures
Study: NCT04019522

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Intermittent Hypoxia (AIH)
Description: An oxygen monitor will continuously measure and record the fraction of inspired oxygen delivered to the subject. Inspired fraction of oxygen (FiO2) of the gas mixture will be individually adjusted using the valve settings to reach the targeted SpO2. The gas mixtures administered during the four sessions will be 21% O2 (target SpO2 = 95%), 17% O2 (target SpO2 = 92%), 13% O2 (target SpO2 = 87%) and 9% O2 (target SpO2 = 82%).
Study: NCT04411082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMR-687
Description: Oral administration of once daily IMR-687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMR-687
Description: Oral administration of once daily IMR-687
Study: NCT00916955

Intervention type: OTHER
Intervention: Observation
Description: Observe development of syndrome over time
Study: NCT04429503

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aflibercept
Description: Intravitreally (IVT) administered as a liquid formulation in a vial
Study: NCT00664027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTA 402 (Bardoxolone Methyl)
Description: Stratum 1: 25, 75, 150mg/day, orally, 28 consecutive days Stratum 2: 25 mg/day, orally, 28 consecutive days followed by 75 mg/day, orally, 28 consecutive days
Study: NCT04429503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose aflibercept
Description: Intravitreally (IVT) administered as a liquid formulation in a vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose aflibercept
Description: Intravitreally (IVT) administered as a liquid formulation in a vial
Study: NCT01665612

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contact lens care solution
Description: Comparison of clinical and subjective performation of the contact lens care solutions used with two types of contact lenses

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Contact lens care solution
Description: Comparison of clinical and subjective performation of the contact lens care solutions used with two types of contact lenses

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Contact lens care solution
Description: Comparison of clinical and subjective performation of the contact lens care solutions used with two types of contact lenses
Study: NCT02793011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral dexamethasone elixir (0.5mg/ml or 4 mg/ml) mixed with Ora-sweet or simple syrup to mask the taste. Or 1 mg or 4 mg dexamethasone capsules if age appropriate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo liquid (Ora-sweet or simple syrup) or Placebo capsule
Study: NCT04243109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide + Cyclophosphamide + Dexamethasone
Description: Treatment Phase: Combination of Pomalidomide, Cyclophosphamide and Dexamethasone, days 1-21 every 4 weeks (28 day cycles), up to a total of 8 cycles:~* Pomalidomide: Treatment with Pomalidomide 4 mg / day 1-21 days in 28-day cycles is started. Dose reductions will be made based on the evaluation of hematological and non-hematological toxicity.~* Cyclophosphamide: Cyclophosphamide will be administered 15 mg / day, days 1-28 in 28-day cycles.~* Dexamethasone: Dexamethasone will be administered 40 mg / day, days 1, 8, 15 and 22 in 28-day cycles. In patients older than 75 years the dose will be reduced to 20 mg / day in the same previous schedule.~Maintenance Phase: Combination of Pomalidomide and Dexamethasone. The last doses prescribed in the previous cycle will be maintained.
Study: NCT03892473

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community mental health teams (CMHT)
Description: Community mental health teams (CMHTs) delivering evidence-based interventions to people with SMI, inspired by the Flexible Assertive Community Treatment (FACT) service delivery model.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Care as usual (CAU)
Description: Care as usual (CAU) usually consisting of inpatient psychiatric care or outpatient care prescribing medication.
Study: NCT02464917

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device: simple facemask to administer supplemental oxygen
Study: NCT01409395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin and nizatidine
Description: Subjects will be given a single oral dose of 850 mg of metformin and a single oral dose of 600 mg of nizatidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Subjects will be given a single oral dose of 850 mg of metformin
Study: NCT02395510

Intervention type: DRUG
Group type: OTHER
Intervention: Vortioxetine
Description: Vortioxetine 5-20mg
Study: NCT03183778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patiromer
Description: Patiromer dosing will be determined based on fasting potassium concentrations measured at the end of each week, factoring in both the absolute concentration, as well as the rate of change. The baseline dose of patiromer will correspond to the study by Weir et al. (2015); 8.4-g once per day for participants with a baseline serum potassium of greater than or equal to 5.1 mEq/L.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Research Diet Menu
Description: During the study, participants will be asked to consume only the foods provided in the research diet